Skip to Main content Skip to Navigation
Journal articles

Préservation de la fertilité, contraception et traitement hormonal de la ménopause chez les femmes traitées pour tumeurs malignes rares de l’ovaire : recommandations du réseau national dédié aux cancers gynécologiques rares (TMRG/GINECO)

Christine Rousset-Jablonski 1 Frédéric Selle 2 Elodie Adda-Herzog François Planchamp Lise Selleret Christophe Pomel 3, 4 Nathalie Chabbert-Buffet 5 Emile Darai 5 Patricia Pautier 6 Florence Trémollières 7 Frédéric Guyon 8 Roman Rouzier 9 Valérie Laurence Nicolas Chopin 10, 1 Cécile Faure-Conter 1 Enrica Bentivegna 11 Marie-Cécile Vacher-Lavenu 12 Catherine Lhomme 11 Anne Floquet 13 Isabelle Treilleux 1, 14 Fabrice Lecuru 15 Sébastien Gouy 11 Elsa Kalbacher 6 Catherine Genestie 16 Thibault de la Motte Rouge 17 Gwenaël Ferron 18 Mojgan Devouassoux-Shisheboran 19 Jean-Emmanuel Kurtz 20 Moïse Namer 21 Florence Joly 22 Eric Pujade-Lauraine 23 Michael Grynberg 24 Denis Querleu 18 Philippe Morice 25 Anne Gompel 26, 12 Isabelle Ray-Coquard 27, 1
Abstract : Introduction - Rare ovarian tumors include complex borderline ovarian tumors, sex-cord tumors, germ cell tumors, and rare epithelial tumors. Indications and modalities of fertility preservation, infertility management and contraindications for hormonal contraception or menopause hormone therapy are frequent issues in clinical practice. A panel of experts from the French national network dedicated to rare gynaecological cancers, and of experts in reproductive medicine and gynaecology have worked on guidelines about fertility preservation, contraception and menopause hormone therapy in women treated for ovarian rare tumors. Methods - A panel of 39 experts from different specialties contributed to the preparation of the guidelines, following the DELPHI method (formal consensus method). Statements were drafted after a systematic literature review, and then rated through two successive rounds. Results - Thirty-five recommendations were selected, and concerned indications for fertility preservation, contraindications for ovarian stimulation (in the context of fertility preservation or for infertility management), contraceptive options (especially hormonal ones), and menopause hormone therapy for each tumor type. Overall, prudence has been recommended in the case of potentially hormone-sensitive tumors such as sex cord tumors, serous and endometrioid low-grade adenocarcinomas, as well as for high-risk serous borderline ovarian tumors. Discussion - In the context of a scarce literature, a formal consensus method allowed the elaboration of guidelines, which will help clinicians in the management of these patients.
Document type :
Journal articles
Complete list of metadatas

https://hal.archives-ouvertes.fr/hal-01926591
Contributor : Mouniati Colo <>
Submitted on : Monday, November 19, 2018 - 12:52:40 PM
Last modification on : Monday, June 29, 2020 - 2:34:08 PM

Identifiers

Citation

Christine Rousset-Jablonski, Frédéric Selle, Elodie Adda-Herzog, François Planchamp, Lise Selleret, et al.. Préservation de la fertilité, contraception et traitement hormonal de la ménopause chez les femmes traitées pour tumeurs malignes rares de l’ovaire : recommandations du réseau national dédié aux cancers gynécologiques rares (TMRG/GINECO). Bulletin du Cancer, John Libbey Eurotext, 2018, 105 (3), pp.299 - 314. ⟨10.1016/j.bulcan.2017.10.032⟩. ⟨hal-01926591⟩

Share

Metrics

Record views

286